%0 Journal Article
%A Marth, Christian
%A Tarnawski, Rafal
%A Tyulyandina, Alexandra
%A Pignata, Sandro
%A Gilbert, Lucy
%A Kaen, Diego
%A Rubio, M. Jesus
%A Frentzas, Sophia
%A Beiner, Mario
%A Magallanes-Maciel, Manuel
%A Farrelly, Laura
%A Choi, Chel Hun
%A Berger, Regina
%A Lee, Christine
%A Vulsteke, Christof
%A Hasegawa, Kosei
%A Braicu, Elena Ioanna
%A Wu, Xiaohua
%A McKenzie, Jodi
%A Lee, John J.
%A Makker, Vicky
%T Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
%D 2021
%@ 1048-891X
%U https://hdl.handle.net/10668/25441
%X Background Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination demonstrated high objective response rates in a single-arm phase 1b/2 trial of lenvatinib plus pembrolizumab in patients with advanced endometrial cancer (KEYNOTE-146/Study 111) after
%~